Bayer to dump $2.26B into manufacturing realignment as it says goodbye to some sites
Bayer is ready to pour billions more into its pharma manufacturing operations, but with that, it will cut ties with several sites it already owns.
Bayer will invest more than $2.26 billion in its pharmaceutical manufacturing over the next three years, as it expands in both Europe and the US. Expansions in Bergkamen, Berlin, Leverkusen, Weimar and Wuppertal were already announced earlier in March in a German-only statement, stating that it will modernize facilities and work on “more intensive collaboration” with area universities and startups.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.